GH Research PLC

NASDAQ:GHRS

8.62 (USD) • At close November 7, 2024
Bedrijfsnaam GH Research PLC
Symbool GHRS
Munteenheid USD
Prijs 8.62
Beurswaarde 448,482,222
Dividendpercentage 0%
52-weken bereik 5.05 - 14.99
Industrie Biotechnology
Sector Healthcare
CEO Dr. Theis Terwey M.D.
Website https://www.ghres.com

An error occurred while fetching data.

Over GH Research PLC

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed

Vergelijkbare Aandelen

PetIQ, Inc. logo

PetIQ, Inc.

PETQ

30.98 USD

Computer Programs and Systems, Inc. logo

Computer Programs and Systems, Inc.

CPSI

9.19 USD

Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc.

STOK

13.27 USD

SI-BONE, Inc. logo

SI-BONE, Inc.

SIBN

15.57 USD

Y-mAbs Therapeutics, Inc. logo

Y-mAbs Therapeutics, Inc.

YMAB

15.55 USD

Affimed N.V. logo

Affimed N.V.

AFMD

3.83 USD

Geron Corporation logo

Geron Corporation

GERN

4.29 USD

Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc.

TNGX

2.83 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)